華峯化學(002064.SZ):前三季度業績預盈58億-62億元,同比增長367.30%-399.52%
格隆匯10月11日丨華峯化學(002064.SZ)公佈,2021年1月1日-2021年9月30日期間,公司預計盈利58億-62億元,與上年同期相比增長367.30%-399.52%。
業績變動原因主要為:
報吿期內,化工行業景氣度持續上升,市場持續向好,公司緊抓市場機遇,實時調整市場策略,同時強化內部管理,提質增效。公司主導產品產銷量、銷售價格較上年同期均有較大幅度增長,整體毛利率顯著上升,盈利情況同比大幅提升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.